BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 17295463)

  • 1. Construction and validation of a RET TK catalytic domain by homology modeling.
    Tuccinardi T; Manetti F; Schenone S; Martinelli A; Botta M
    J Chem Inf Model; 2007; 47(2):644-55. PubMed ID: 17295463
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Computational proteomics of biomolecular interactions in the sequence and structure space of the tyrosine kinome: deciphering the molecular basis of the kinase inhibitors selectivity.
    Verkhivker GM
    Proteins; 2007 Mar; 66(4):912-29. PubMed ID: 17173284
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Homology models of the mutated EGFR and their response towards quinazoline analogues.
    Kotra S; Madala KK; Jamil K
    J Mol Graph Model; 2008 Oct; 27(3):244-54. PubMed ID: 18585943
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structural insights into the ATP binding pocket of the anaplastic lymphoma kinase by site-directed mutagenesis, inhibitor binding analysis, and homology modeling.
    Gunby RH; Ahmed S; Sottocornola R; Gasser M; Redaelli S; Mologni L; Tartari CJ; Belloni V; Gambacorti-Passerini C; Scapozza L
    J Med Chem; 2006 Sep; 49(19):5759-68. PubMed ID: 16970400
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of c-Met kinase domain complexes: a new specific catalytic site receptor model for defining binding modes of ATP-competitive ligands.
    Asses Y; Leroux V; Tairi-Kellou S; Dono R; Maina F; Maigret B
    Chem Biol Drug Des; 2009 Dec; 74(6):560-70. PubMed ID: 19909299
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Receptor-based 3D-QSAR studies of checkpoint Wee1 kinase inhibitors.
    Wichapong K; Lindner M; Pianwanit S; Kokpol S; Sippl W
    Eur J Med Chem; 2009 Apr; 44(4):1383-95. PubMed ID: 18976834
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Determination of the structure of human phosphodiesterase-2 in a bound state and its binding with inhibitors by molecular modeling, docking, and dynamics simulation.
    Hamza A; Zhan CG
    J Phys Chem B; 2009 Mar; 113(9):2896-908. PubMed ID: 19708117
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Homology modeling and receptor-based 3D-QSAR study of carbonic anhydrase IX.
    Tuccinardi T; Ortore G; Rossello A; Supuran CT; Martinelli A
    J Chem Inf Model; 2007; 47(6):2253-62. PubMed ID: 17949069
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Kinases, homology models, and high throughput docking.
    Diller DJ; Li R
    J Med Chem; 2003 Oct; 46(22):4638-47. PubMed ID: 14561083
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structural biology contributions to tyrosine kinase drug discovery.
    Cowan-Jacob SW; Möbitz H; Fabbro D
    Curr Opin Cell Biol; 2009 Apr; 21(2):280-7. PubMed ID: 19208462
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In silico profiling of tyrosine kinases binding specificity and drug resistance using Monte Carlo simulations with the ensembles of protein kinase crystal structures.
    Verkhivker GM
    Biopolymers; 2007 Mar; 85(4):333-48. PubMed ID: 17167796
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Homology modeling, agonist binding site identification, and docking in octopamine receptor of Periplaneta americana.
    Hirashima A; Huang H
    Comput Biol Chem; 2008 Jun; 32(3):185-90. PubMed ID: 18430608
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structure modeling, ligand binding, and binding affinity calculation (LR-MM-PBSA) of human heparanase for inhibition and drug design.
    Zhou Z; Bates M; Madura JD
    Proteins; 2006 Nov; 65(3):580-92. PubMed ID: 16972282
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Homology modeling of human transketolase: description of critical sites useful for drug design and study of the cofactor binding mode.
    Obiol-Pardo C; Rubio-Martinez J
    J Mol Graph Model; 2009 Feb; 27(6):723-34. PubMed ID: 19111488
    [TBL] [Abstract][Full Text] [Related]  

  • 15. IKKbeta inhibitors identification part I: homology model assisted structure based virtual screening.
    Nagarajan S; Doddareddy Mr; Choo H; Cho YS; Oh KS; Lee BH; Pae AN
    Bioorg Med Chem; 2009 Apr; 17(7):2759-66. PubMed ID: 19285872
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rationalizing protein-ligand interactions for PTP1B inhibitors using computational methods.
    Ajmani S; Karanam S; Kulkarni SA
    Chem Biol Drug Des; 2009 Dec; 74(6):582-95. PubMed ID: 19824894
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Computational studies of tryptophanyl-tRNA synthetase: activation of ATP by induced-fit.
    Kapustina M; Carter CW
    J Mol Biol; 2006 Oct; 362(5):1159-80. PubMed ID: 16949606
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Importance of molecular computer modeling in anticancer drug development.
    Geromichalos GD
    J BUON; 2007 Sep; 12 Suppl 1():S101-18. PubMed ID: 17935268
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Docking essential dynamics eigenstructures.
    Mustard D; Ritchie DW
    Proteins; 2005 Aug; 60(2):269-74. PubMed ID: 15981272
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Binding interaction analysis of the active site and its inhibitors for neuraminidase (N1 subtype) of human influenza virus by the integration of molecular docking, FMO calculation and 3D-QSAR CoMFA modeling.
    Zhang Q; Yang J; Liang K; Feng L; Li S; Wan J; Xu X; Yang G; Liu D; Yang S
    J Chem Inf Model; 2008 Sep; 48(9):1802-12. PubMed ID: 18707092
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.